code
stringlengths 7
7
| procedure
stringlengths 8
198
|
|---|---|
XW0V0P7 | Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7 |
XW0V3WA | Introduction of AGN1 Bone Void Filler into Bones, Percutaneous Approach, New Technology Group 10 |
XW13325 | Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW1337A | Transfusion of Marnetegragene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW133B8 | Transfusion of Betibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW133C8 | Transfusion of Omidubicel into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW133D7 | Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW133E7 | Transfusion of Hyperimmune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW133F8 | Transfusion of OTL-103 into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW133G8 | Transfusion of OTL-200 into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW133H9 | Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
XW133J8 | Transfusion of Exagamglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW14325 | Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5 |
XW1437A | Transfusion of Marnetegragene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW143B8 | Transfusion of Betibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW143C8 | Transfusion of Omidubicel into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW143D7 | Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW143E7 | Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW143F8 | Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW143G8 | Transfusion of OTL-200 into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW143H9 | Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9 |
XW143J8 | Transfusion of Exagamglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 |
XWHD7Q7 | Insertion of Neurostimulator Lead into Mouth and Pharynx, Via Natural or Artificial Opening, New Technology Group 7 |
XX20X89 | Monitoring of Brain Electrical Activity, Computer-aided Detection and Notification, New Technology Group 9 |
XX25X0A | Monitoring of Blood Flow, Adhesive Ultrasound Patch Technology, New Technology Group 10 |
XX2F3W9 | Monitoring of Musculoskeletal Muscle Compartment Pressure, Micro-Electro-Mechanical System, Percutaneous Approach, New Technology Group 9 |
XX2KXP9 | Monitoring of Interstitial Fluid Volume, Sub-Epidermal Moisture using Electrical Biocapacitance, External Approach, New Technology Group 9 |
XXA536A | Circulatory Filtration, Blood Pathogens, Percutaneous Approach, New Technology Group 10 |
XXE0X07 | Measurement of Intracranial Vascular Activity, Computer-aided Assessment, New Technology Group 7 |
XXE0X1A | Measurement of Intracranial Cerebrospinal Fluid Flow, Computer-aided Triage and Notification, New Technology Group 10 |
XXE0X48 | Measurement of Brain Electrical Activity, Computer-aided Semiologic Analysis, New Technology Group 8 |
XXE2X19 | Measurement of Cardiac Output, Computer-aided Assessment, New Technology Group 9 |
XXE3X27 | Measurement of Pulmonary Artery Flow, Computer-aided Triage and Notification, New Technology Group 7 |
XXE3X58 | Measurement of Coronary Artery Flow, Quantitative Flow Ratio Analysis, New Technology Group 8 |
XXE3X68 | Measurement of Coronary Artery Flow, Computer-aided Valve Modeling and Notification, New Technology Group 8 |
XXE5X2A | Measurement of Infection, Phenotypic Fully Automated Rapid Susceptibility Technology with Controlled Inoculum, New Technology Group 10 |
XXE5X38 | Measurement of Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction, New Technology Group 8 |
XXE5X4A | Measurement of Infection, Positive Blood Culture Small Molecule Sensor Array Technology, New Technology Group 10 |
XXE5XN6 | Measurement of Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility, New Technology Group 6 |
XXE5XR7 | Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7 |
XXE5XT7 | Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7 |
XXE5XV7 | Measurement of Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection, New Technology Group 7 |
XXE5XY9 | Measurement of Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, New Technology Group 9 |
XXE97U7 | Measurement of Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, New Technology Group 7 |
XXEBXQ6 | Measurement of Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection, New Technology Group 6 |
XY0VX83 | Extracorporeal Introduction of Endothelial Damage Inhibitor to Vein Graft, New Technology Group 3 |
XY0YX28 | Extracorporeal Introduction of Taurolidine Anti-infective and Heparin Anticoagulant, New Technology Group 8 |
XY0YX37 | Extracorporeal Introduction of Nafamostat Anticoagulant, New Technology Group 7 |